FLT1

Across TCGA pan-cancer cohorts, FLT1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of FLT1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FLT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FLT1 is over-expressed in tumor, although a few such as KIRP and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where FLT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FLT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+2.430	<.001	12	view →
HNSC	Female	IV	+2.245	<.001	12	view →
LIHC	Female	II,III,IV	+1.350	<.001	9	view →
KIRP	Male	All	−1.848	<.001	7	view →
LUSC	All	II,III,IV	−0.863	<.001	7	view →
BRCA	All	All	−0.417	<.001	6	view →
READ	Male	All	+2.026	.002	5	view →
STAD	Male	II,III,IV	+1.220	<.001	5	view →
COAD	Male	II,III,IV	+0.580	.020	4	view →
KICH	All	III,IV	−1.238	.003	3	view →
THCA	All	IV	−1.832	.014	2	view →
CHOL	All	All	+1.286	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

FLT1–KIRC

Open the KIRC breakdown →